Source: International Congress 2019 – New towards old therapies in airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Conde Garcia (Paris, France), R. Bertrand (Paris, France), B. Balbino (Paris, France), J. Bonnefoy (Paris, France), J. Stackowicz (Paris, France), N. Caillot (Paris, France), F. Colaone (Paris, France), S. Hamdi (Paris, France), P. Bruhns (Paris, France), V. Serra (Paris, France), G. Grouard-Vogel (Paris, France), L. Reber (Paris, France). Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice. 2102

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Effects of anti-IL-1α, anti-IL-1β, anti-IL-18 and anti-IL-1RI antibodies on combined smoke and virus-induced airway inflammation in mice Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations Source: Eur Respir J 2001; 18: 249-250 Year: 2001 Late Breaking Abstract - IL-33 drives influenza-induced exacerbations of asthma by halting anti-viral and Th1 responses Source: International Congress 2017 – Animal models of asthma and allergies Year: 2017 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005 Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Novel inhaled delivery of anti-IL-13 mAb (Fab fragment): preclinical efficacy in allergic asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Late Breaking Abstract - Systemic IL-26 correlates with improved asthma control in children with allergic sensitization Source: International Congress 2018 – Molecular and cellular determinants of the developing lung Year: 2018 Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients. Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Tolerability assessment of a recombinant humanized monoclonal anti-IgE antibody (omalizumab) as a treatment for seasonal allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002 Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Study of regulative effect of anti-IL-4 monoclone antibody on Th1/Th2 in the patients of allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020 Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021